Clinical Trial Update: Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy results were posted in 2017 for a Bruton tyrosine kinase (BTK) inhibitor in patients with relapsed or refractory diffuse large B-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Diffuse Large Cell B-lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-16